New Paper Issued on Lupus


The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis


Modern Rheumatology, roac010, https://doi.org/10.1093/mr/roac010
Published:
 
22 February 2022

https://academic.oup.com/mr/advance-article/doi/10.1093/mr/roac010/6521716?login=true


ABSTRACT

Objectives

Evaluate the efficacy and safety of anifrolumab in the subpopulation of Japanese patients with systemic lupus erythematosus (SLE) in the phase 3 TULIP-2 trial.

Methods

TULIP-2 was a 52-week randomized placebo-controlled trial (N=362) that evaluated efficacy and safety of anifrolumab 300 mg IV every 4 weeks vs. placebo in patients with moderate to severe SLE, and were receiving standard therapy. We performed a post hoc analysis of the primary and key secondary endpoints, and safety, of TULIP-2 in the Japanese subpopulation.

Results

In the Japanese subpopulation (anifrolumab, n=24; placebo, n=19), the proportion of patients who achieved a British Isles Lupus Assessment Group–based Composite Lupus Assessment response at Week 52 (primary endpoint) was greater in the anifrolumab group vs. placebo (50.0% [12/24] vs. 15.8% [3/19]; treatment difference: 34.2%, 95% confidence interval 6.9, 61.5; nominal P=0.014). Improvement in skin activity and flare rates (key secondary endpoints) were favorable for anifrolumab vs. placebo. Consistent with the overall population, anifrolumab had an acceptable safety and tolerability profile.

Conclusions

The efficacy and safety of anifrolumab 300 mg in Japanese patients with SLE was consistent with the demonstrated clinical profile of anifrolumab for the overall TULIP-2 population.

Comments

Post a Comment

Popular posts from this blog

THE CURRENT WAR: A GREAT FILM ABOUT INVENTIONS AND PATENTS So my wife and I recently watched a terrific film which was actually released back in 2017, called "The Current War", which is about Edison and Westinghouse battling over whether AC (Alternating Current" or DC (Direct Current) would become the standard for electrification of the United States.   The film is quite literally about inventions, patents, and highlights the critical importance of intellectual property as early as the 1880s in securing the greatest value for your business enterprise.   Highly recommended for everyone in the industry; and for science students, law students interested in IP, and anyone interested in the history of IP.   https://www.imdb.com/title/tt2140507/  
Read more
Winnie the Pooh - Public Domain v Trademark Ownership   Brett Trout Esq. has written a terrific blog post on Public Domain v. Trademark Rights in a very funny article about Winnie the Pooh by AA Milne: https://blawgit.com/2022/01/22/who-owns-the-pooh/ In part, he states: As of January 1, 2022 Winnie the Pooh entered the public domain. But what does that mean?  Can you write a book about Winnie the Pooh and Tigger too? No.  Can you sell Winnie the Pooh branded socks? No.  Can you start a Winnie the Pooh comic strip? Probably not.  But why? The answer is that although the original copyright in Winnie the Pooh has moved into the public domain, the copyrights in all of his friends and all of the books published after 1926 are still in force. More importantly, all of the trademarks covering Winnie the Pooh goods and services are still in force and may never expire.  Id.
Read more
USPTO TO STOP ISSUING PAPER PATENT GRANT CERTIFICATES Jim Singer, Esq. has posted a great blog on his blogsite pointing out that the USPTO will no longer be routinely giving out paper patent grants with the certificate and ribbon. Those certificates were long prized by inventors, and many of them would frame them and put them on their walls; others of course, did not such thing. The good news is, you can still get the paper certificate with all the bells and whistles, but you will (as always with the USPTO) have to pay an extra fee. Here's the link to Jim's great article: https://ipspotlight.com/2021/12/13/end-of-an-era-uspto-proposes-to-phase-out-hard-copy-patent-and-trademark-certificates/
Read more